Vivos Therapeutics Inc
NASDAQ:VVOS
Balance Sheet
Balance Sheet Decomposition
Vivos Therapeutics Inc
Vivos Therapeutics Inc
Balance Sheet
Vivos Therapeutics Inc
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
1
|
0
|
18
|
24
|
4
|
2
|
6
|
|
| Cash Equivalents |
1
|
0
|
18
|
24
|
4
|
2
|
6
|
|
| Total Receivables |
1
|
1
|
2
|
1
|
0
|
0
|
0
|
|
| Accounts Receivables |
1
|
1
|
2
|
1
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
1
|
2
|
1
|
1
|
1
|
|
| Total Current Assets |
2
|
2
|
20
|
27
|
5
|
2
|
7
|
|
| PP&E Net |
1
|
1
|
1
|
3
|
5
|
5
|
4
|
|
| PP&E Gross |
1
|
1
|
1
|
3
|
5
|
5
|
4
|
|
| Accumulated Depreciation |
0
|
1
|
1
|
1
|
2
|
2
|
3
|
|
| Intangible Assets |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Goodwill |
4
|
3
|
3
|
3
|
3
|
3
|
3
|
|
| Note Receivable |
0
|
1
|
1
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
4
|
3
|
3
|
3
|
3
|
3
|
3
|
|
| Total Assets |
8
N/A
|
8
-8%
|
25
+235%
|
34
+33%
|
14
-59%
|
11
-22%
|
15
+42%
|
|
| Liabilities | ||||||||
| Accounts Payable |
0
|
1
|
2
|
1
|
1
|
2
|
1
|
|
| Accrued Liabilities |
1
|
1
|
2
|
3
|
2
|
3
|
3
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
4
|
1
|
1
|
0
|
0
|
0
|
|
| Other Current Liabilities |
1
|
3
|
3
|
2
|
3
|
2
|
1
|
|
| Total Current Liabilities |
2
|
9
|
8
|
8
|
7
|
7
|
5
|
|
| Long-Term Debt |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
2
|
3
|
2
|
|
| Total Liabilities |
3
N/A
|
9
+239%
|
8
-8%
|
8
-3%
|
9
+9%
|
10
+16%
|
7
-29%
|
|
| Equity | ||||||||
| Common Stock |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
13
|
23
|
35
|
56
|
79
|
93
|
104
|
|
| Additional Paid In Capital |
17
|
20
|
52
|
81
|
84
|
93
|
112
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
5
N/A
|
2
N/A
|
17
N/A
|
26
+51%
|
5
-81%
|
0
-91%
|
8
+1 835%
|
|
| Total Liabilities & Equity |
8
N/A
|
8
-8%
|
25
+235%
|
34
+33%
|
14
-59%
|
11
-22%
|
15
+42%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
1
|
1
|
1
|
1
|
1
|
2
|
6
|
|